Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$95.90
al cierre: Oct 8 EDT
$95.39
-0.51-0.54%
Pre-comercialización: 7:43 AM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Boston Scientific Corp ha un obiettivo di prezzo di consenso pari a $117.08, stabilito in base alle ultime valutazioni degli analisti di 25. Le ultime 3 valutazioni degli analisti sono state rilasciate da Evercore ISI Group, Barclays y Truist Securities il octubre 7, 2025, octubre 2, 2025 y octubre 1, 2025. Con un obiettivo di prezzo medio di $125 tra le Evercore ISI Group, Barclays y Truist Securities, c'è un implicito 31.05% upside per Boston Scientific Corp da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Evercore ISI Group
Barclays
Truist Securities
Canaccord Genuity
Baird
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Boston Scientific
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/07/2025 | 15.32% | Evercore ISI Group | $115 → $110 | Maintains | Outperform | |||
10/02/2025 | 42.58% | Barclays | $133 → $136 | Maintains | Overweight | |||
10/01/2025 | 35.24% | Truist Securities | $125 → $129 | Maintains | Buy | |||
10/01/2025 | 38.38% | Canaccord Genuity | $131 → $132 | Maintains | Buy | |||
10/01/2025 | 34.19% | Baird | $123 → $128 | Maintains | Outperform | |||
10/01/2025 | 34.19% | Leerink Partners | $127 → $128 | Maintains | Outperform | |||
10/01/2025 | 26.85% | Needham | $121 → $121 | Reiterates | Buy → Buy | |||
10/01/2025 | 38.38% | BTIG | $127 → $132 | Maintains | Buy | |||
09/29/2025 | 31.05% | RBC Capital | $125 → $125 | Reiterates | Outperform → Outperform | |||
09/23/2025 | 33.14% | BTIG | $127 → $127 | Reiterates | Buy → Buy | |||
09/19/2025 | 26.85% | Needham | $121 → $121 | Reiterates | Buy → Buy | |||
09/11/2025 | 26.85% | Needham | $121 → $121 | Reiterates | Buy → Buy | |||
09/08/2025 | 31.05% | Oppenheimer | $118 → $125 | Upgrade | Perform → Outperform | |||
07/24/2025 | 41.53% | UBS | $130 → $135 | Maintains | Buy | |||
07/24/2025 | 30% | Raymond James | $121 → $124 | Maintains | Strong Buy | |||
07/24/2025 | 23.71% | Oppenheimer | $110 → $118 | Maintains | Perform | |||
07/24/2025 | 30% | Wells Fargo | $118 → $124 | Maintains | Overweight | |||
07/24/2025 | 31.05% | Truist Securities | $120 → $125 | Maintains | Buy | |||
07/24/2025 | 28.95% | Baird | $117 → $123 | Maintains | Outperform | |||
07/24/2025 | 39.43% | Barclays | $125 → $133 | Maintains | Overweight | |||
06/16/2025 | 23.71% | Leerink Partners | → $118 | Initiates | → Outperform | |||
05/28/2025 | 20.56% | Needham | $115 → $115 | Reiterates | Buy → Buy | |||
05/22/2025 | 31.05% | Citigroup | $119 → $125 | Maintains | Buy | |||
05/16/2025 | 31.05% | Morgan Stanley | $120 → $125 | Maintains | Overweight | |||
04/25/2025 | 31.05% | Barclays | $118 → $125 | Maintains | Overweight | |||
04/24/2025 | 26.85% | Raymond James | $122 → $121 | Maintains | Strong Buy | |||
04/24/2025 | 20.56% | Needham | $113 → $115 | Maintains | Buy | |||
04/24/2025 | 25.8% | RBC Capital | $116 → $120 | Maintains | Outperform | |||
04/24/2025 | 22.66% | Truist Securities | $113 → $117 | Maintains | Buy | |||
04/24/2025 | 17.42% | Evercore ISI Group | $110 → $112 | Maintains | Outperform | |||
04/24/2025 | 25.8% | Baird | $115 → $120 | Maintains | Outperform | |||
04/23/2025 | 30% | BTIG | $120 → $124 | Maintains | Buy | |||
04/16/2025 | 18.47% | Needham | → $113 | Upgrade | Hold → Buy | |||
04/11/2025 | 18.47% | Truist Securities | $120 → $113 | Maintains | Buy | |||
03/03/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
02/10/2025 | 25.8% | Stifel | $115 → $120 | Maintains | Buy | |||
02/10/2025 | 23.71% | Barclays | $111 → $118 | Maintains | Overweight | |||
02/07/2025 | 36.29% | UBS | $105 → $130 | Maintains | Buy | |||
02/06/2025 | 25.8% | Truist Securities | $110 → $120 | Maintains | Buy | |||
02/06/2025 | 22.66% | Canaccord Genuity | $101 → $117 | Maintains | Buy | |||
02/06/2025 | 20.56% | Baird | $100 → $115 | Maintains | Outperform | |||
02/06/2025 | 27.9% | Raymond James | $119 → $122 | Maintains | Strong Buy | |||
02/06/2025 | 21.61% | RBC Capital | $105 → $116 | Maintains | Outperform | |||
02/06/2025 | 20.56% | Stifel | $100 → $115 | Maintains | Buy | |||
02/06/2025 | 23.71% | Wells Fargo | $100 → $118 | Maintains | Overweight | |||
02/06/2025 | 27.9% | Citigroup | $107 → $122 | Maintains | Buy | |||
02/06/2025 | 25.8% | Morgan Stanley | $100 → $120 | Maintains | Overweight | |||
02/06/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
02/03/2025 | 20.56% | Piper Sandler | $95 → $115 | Maintains | Overweight | |||
01/31/2025 | 24.76% | Raymond James | $101 → $119 | Maintains | Strong Buy | |||
12/30/2024 | 5.88% | BTIG | $97 → $101 | Maintains | Buy | |||
12/18/2024 | 10.08% | RBC Capital | $98 → $105 | Maintains | Outperform | |||
12/18/2024 | 15.32% | Truist Securities | $100 → $110 | Maintains | Buy | |||
12/16/2024 | 15.32% | JP Morgan | $100 → $110 | Maintains | Overweight | |||
12/12/2024 | 15.32% | TD Cowen | $100 → $110 | Maintains | Buy | |||
12/11/2024 | 12.17% | Citigroup | $98 → $107 | Maintains | Buy | |||
12/11/2024 | 4.84% | Wells Fargo | $98 → $100 | Maintains | Overweight | |||
12/09/2024 | 5.88% | Canaccord Genuity | $98 → $101 | Maintains | Buy | |||
11/27/2024 | — | Needham | — | Reiterates | → Hold | |||
11/18/2024 | — | Needham | — | Reiterates | → Hold | |||
10/31/2024 | — | Needham | — | Reiterates | → Hold | |||
10/24/2024 | 4.84% | Bernstein | $92 → $100 | Maintains | Outperform | |||
10/24/2024 | 4.84% | Morgan Stanley | $92 → $100 | Maintains | Overweight | |||
10/24/2024 | 2.74% | RBC Capital | $95 → $98 | Maintains | Outperform | |||
10/24/2024 | 2.74% | Wells Fargo | $87 → $98 | Maintains | Overweight | |||
10/24/2024 | 2.74% | Citigroup | $92 → $98 | Maintains | Buy | |||
10/24/2024 | 2.74% | Canaccord Genuity | $98 → $98 | Maintains | Buy | |||
10/24/2024 | 15.32% | Mizuho | $100 → $110 | Maintains | Outperform | |||
10/24/2024 | — | Needham | — | Reiterates | → Hold | |||
10/23/2024 | 1.69% | BTIG | $93 → $97 | Maintains | Buy | |||
10/22/2024 | 4.84% | B of A Securities | $90 → $100 | Maintains | Buy | |||
10/21/2024 | 4.84% | TD Cowen | $86 → $100 | Maintains | Buy | |||
10/21/2024 | 2.74% | Canaccord Genuity | $88 → $98 | Maintains | Buy | |||
10/18/2024 | 4.84% | Stifel | $85 → $100 | Maintains | Buy | |||
10/18/2024 | -9.84% | Needham | $86 → $86 | Downgrade | Buy → Hold | |||
10/15/2024 | 4.84% | Baird | $91 → $100 | Maintains | Outperform | |||
10/14/2024 | -2.5% | BTIG | $84 → $93 | Maintains | Buy | |||
10/14/2024 | 4.84% | Truist Securities | $90 → $100 | Maintains | Buy | |||
10/08/2024 | -0.41% | RBC Capital | $85 → $95 | Maintains | Outperform | |||
10/01/2024 | -5.65% | Evercore ISI Group | $82 → $90 | Maintains | Outperform | |||
09/04/2024 | -1.45% | Raymond James | $91 → $94 | Maintains | Strong Buy | |||
08/22/2024 | -3.55% | Citigroup | $90 → $92 | Maintains | Buy | |||
08/22/2024 | -9.84% | Barclays | $78 → $86 | Maintains | Overweight | |||
07/25/2024 | -4.6% | Raymond James | $85 → $91 | Maintains | Strong Buy | |||
07/25/2024 | -18.23% | Deutsche Bank | $73 → $78 | Maintains | Hold | |||
07/25/2024 | -10.89% | RBC Capital | $85 → $85 | Reiterates | Outperform → Outperform | |||
07/25/2024 | -10.89% | JP Morgan | $82 → $85 | Maintains | Overweight | |||
07/25/2024 | -7.74% | Canaccord Genuity | $83 → $88 | Maintains | Buy | |||
07/25/2024 | -4.6% | Baird | $90 → $91 | Maintains | Outperform | |||
07/25/2024 | -9.84% | Needham | $82 → $86 | Maintains | Buy | |||
07/16/2024 | -9.84% | TD Cowen | $77 → $86 | Maintains | Buy | |||
07/16/2024 | -5.65% | Truist Securities | $86 → $90 | Maintains | Buy | |||
07/15/2024 | -11.94% | BTIG | $80 → $84 | Maintains | Buy | |||
07/15/2024 | -3.55% | Morgan Stanley | $79 → $92 | Maintains | Overweight | |||
07/10/2024 | -5.65% | Citigroup | $87 → $90 | Maintains | Buy | |||
07/02/2024 | -15.08% | Evercore ISI Group | $78 → $81 | Maintains | Outperform | |||
06/18/2024 | -14.03% | Needham | $82 → $82 | Reiterates | Buy → Buy | |||
05/30/2024 | -5.65% | Goldman Sachs | → $90 | Initiates | → Buy | |||
05/28/2024 | -0.41% | Argus Research | $80 → $95 | Maintains | Buy | |||
05/22/2024 | -8.79% | Citigroup | $85 → $87 | Maintains | Buy |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Boston Scientific (BSX)?
El último precio objetivo de Boston Scientific (NYSE:BSX) fue comunicado por Evercore ISI Group el octubre 7, 2025. La firma de analistas fijó un precio objetivo para $110.00 que espera BSX a rise dentro de 12 meses (un posible 15.32% upside). 78 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Boston Scientific (BSX)?
La última calificación de analistas para Boston Scientific (NYSE:BSX) fue proporcionada por Evercore ISI Group, y Boston Scientific mantuvo su outperform calificación.
¿Cuándo se produjo la última revisión al alza de Boston Scientific (BSX)?
La última revisión al alza de Boston Scientific Corp se produjo en septiembre 8, 2025, cuando Oppenheimer elevó su precio objetivo a $125. Oppenheimer anteriormente tenía a perform para Boston Scientific Corp.
¿Cuándo fue la última revisión a la baja de Boston Scientific (BSX)?
La última revisión a la baja de Boston Scientific Corp se produjo en octubre 18, 2024, cuando Needham cambió su precio objetivo de $86 a $86 para Boston Scientific Corp.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Boston Scientific (BSX)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Boston Scientific, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Boston Scientific se registró el octubre 7, 2025, por lo que la próxima calificación estará disponible en torno al octubre 7, 2026.
¿Es correcta la calificación de los analistas sobre Boston Scientific (BSX)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Boston Scientific (BSX) fue un mantuvo con un precio objetivo de $115.00 a $110.00. El precio actual al que cotiza Boston Scientific (BSX) es de $95.39, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.